Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone + diltiazem versus valsartan + amlodipine for uncontrolled hypertension with obstructive sleep apnea
ChiCTR2600134229Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Feb 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of eplerenone, diltiazem, valsartan and amlodipine in hypertension (HTN) and obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Office blood pressure control rate at 6 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
eplerenonediltiazemvalsartanamlodipine
03
Conditions
hypertension (HTN)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2600134229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134229.